Find cancer at the first appointment.
We are developing a test that reads a drop of serum in about 90 seconds, with photonics and machine learning, so the answer can come in the room.
We are working with:
- 90 secs from a drop to a score, in the room, no lab
- 1 drop of serum, one single-use cartridge
- 4 in 5 cystoscopies today find no cancer
- 2,600+ human samples in our certified biobank
The problem
Imagine the answer at that first appointment.
Blood in the urine, or a PSA result in the grey zone, starts a long referral pathway: weeks or months of waiting, then a camera or a needle. Most of those procedures find no cancer. Serox aims to answer the question in the room, before the referral.
- 01
Rule out before the camera
Four in five cystoscopies find no cancer. A blood test at the first appointment could tell many patients they don't need one.
- 02
Decide inside the grey zone
Every ambiguous PSA result feeds the MRI queue, and most biopsies find nothing. Serox reads the same blood draw, before MRI or biopsy.
- 03
Free up the pathway
Fewer unnecessary scopes, scans and biopsies means shorter queues for the patients who do need them, at a fraction of the cost.
Serox Limited
A working device: drop to score on real hardware.
One instrument. Many cancers. Same box, same cartridge, same 90 seconds. The only thing that changes is the model.
- 01
The whole fingerprint
Not a single-biomarker test: the spectrum represents every molecule in the drop, so a new cancer is a new model, not a new chemistry.
- 02
The doctor picks the cancer
One cartridge per test, run for the question the clinician needs answered: bladder first, then prostate.
- 03
Built on real samples
Our models are built and tested on more than 2,600 human samples held in our own certified biobank.
Raman is century-old physics. What changed: the hardware got cheap, and machine learning can read it.
Find out at the first appointment.
Come and see it for yourself. Investors, clinicians and partners: we will show you the device working, from drop to score.
